Serotonin receptors are found in almost all animals and are even known to regulate longevity and behavioral aging in the primitive
nematode, Caenorhabditis elegans.[5][6]
Classification
5-hydroxytryptamine receptors or 5-HT receptors, or serotonin receptors are found in the
central and
peripheral nervous systems.[1][2]
They can be divided into 7 families of
G protein-coupled receptors which activate an
intracellularsecond messenger cascade to produce an excitatory or inhibitory response. The exception to this is the
5-HT3 receptor which is a
ligand-gated ion channel.
In 2014, a novel 5-HT receptor was isolated from the small white butterfly,
Pieris rapae, and named pr5-HT8. It does not occur in mammals and shares relatively low similarity to the known 5-HT receptor classes.[7]
The 7 general serotonin receptor classes include a total of 14 known serotonin receptors.[9] The 15th receptor 5-HT1P has been distinguished on the basis of functional and radioligand binding studies, its existence has never been definitely affirmed or refuted.[10][11] The specific types have been characterized as follows:[12][13][14]
Information on serotonin receptors (human isoforms if nothing else is stated)
Note that there is no 5-HT1C receptor since, after the receptor was cloned and further characterized, it was found to have more in common with the 5-HT2 family of receptors and was redesignated as the 5-HT2C receptor.[107]
The genes coding for serotonin receptors are expressed across the mammalian brain. Genes coding for different receptors types follow different developmental curves. Specifically, there is a developmental increase of HTR5A expression in several subregions of the human cortex, paralleled by a decreased expression of HTR1A from the embryonic period to the post-natal one.
[108]
5-HT1-like
A number of receptors were classed as "5-HT1-like" - by 1998 it was being argued that, since these receptors were "a heterogeneous population of 5-HT1B, 5-HT1D and 5-HT7" receptors the classification was redundant.[109]
^Murakami H, Bessinger K, Hellmann J, Murakami S (July 2008). "Manipulation of serotonin signal suppresses early phase of behavioral aging in Caenorhabditis elegans". Neurobiology of Aging. 29 (7): 1093–1100.
doi:
10.1016/j.neurobiolaging.2007.01.013.
PMID17336425.
S2CID37671716.
^Qi YX, Xia RY, Wu YS, Stanley D, Huang J, Ye GY (December 2014). "Larvae of the small white butterfly, Pieris rapae, express a novel serotonin receptor". Journal of Neurochemistry. 131 (6): 767–777.
doi:
10.1111/jnc.12940.
PMID25187179.
S2CID21621635.
^Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE (November 1998). "The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells". European Journal of Pharmacology. 361 (2–3): 299–309.
doi:
10.1016/S0014-2999(98)00744-4.
PMID9865521.
^Malenka RC, Nestler EJ, Hyman SE (2009). Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 4.
ISBN9780071481274. Similarly, little is known about which of serotonin's 14 known receptors must be activated to achieve an antidepressant response.
^Brady ST (2012). Basic Neurochemistry - Principles of Molecular, Cellular and Medical Neurobiology (8th ed.). Waltham, MA: USA: Elsevier. pp. 320–321.
ISBN978-0-12-374947-5.
^
abcdMitchell NA, Pepperell E, Ociepka S, Brown JD, Witherington J, Tuladhar B, et al. (July 2009). "5-hydroxyindalpine, an agonist at the putative 5-HT receptor, has no activity on human recombinant monoamine receptors but accelerates distension-induced peristalsis in mouse isolated colon". Neurogastroenterology and Motility. 21 (7): 760–e48.
doi:
10.1111/j.1365-2982.2009.01275.x.
PMID19309442.
S2CID9532359.
^Glennon RA, Dukat M, Westkaemper RB (2000-01-01).
"Serotonin Receptor Subtypes and Ligands". American College of Neurophyscopharmacology.
Archived from the original on 21 April 2008. Retrieved 2008-04-11.
^"5-Hydroxytryptamine Receptors". IUPHAR Receptor Database. International Union of Basic and Clinical Pharmacology. Retrieved 2008-04-11.
^Tomkins DM, Higgins GA, Sellers EM (June 1994). "Low doses of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake". Psychopharmacology. 115 (1–2): 173–179.
doi:
10.1007/BF02244769.
PMID7862892.
S2CID38012716.
^Müller CP, Carey RJ, Huston JP, De Souza Silva MA (February 2007). "Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors". Progress in Neurobiology. 81 (3): 133–178.
doi:
10.1016/j.pneurobio.2007.01.001.
PMID17316955.
S2CID42788995.
^Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP (February 2005). "Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects". Brain Research. 1034 (1–2): 162–171.
doi:
10.1016/j.brainres.2004.12.012.
PMID15713268.
S2CID28356741.
^
abde Boer SF, Koolhaas JM (December 2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis". European Journal of Pharmacology. 526 (1–3): 125–139.
doi:
10.1016/j.ejphar.2005.09.065.
PMID16310183.
^Ebenezer IS, Arkle MJ, Tite RM (May 2007). "8-Hydroxy-2-(di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors". Methods and Findings in Experimental and Clinical Pharmacology. 29 (4): 269–272.
doi:
10.1358/mf.2007.29.4.1075362.
PMID17609739.
^
abWouters W, Tulp MT, Bevan P (May 1988). "Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors". European Journal of Pharmacology. 149 (3): 213–223.
doi:
10.1016/0014-2999(88)90651-6.
PMID2842163.
^
abHoriuchi J, McDowall LM, Dampney RA (November 2008). "Role of 5-HT(1A) receptors in the lower brainstem on the cardiovascular response to dorsomedial hypothalamus activation". Autonomic Neuroscience. 142 (1–2): 71–76.
doi:
10.1016/j.autneu.2008.06.004.
PMID18667366.
S2CID20878941.
^Nalivaiko E, Ootsuka Y, Blessing WW (August 2005). "Activation of 5-HT1A receptors in the medullary raphe reduces cardiovascular changes elicited by acute psychological and inflammatory stresses in rabbits". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 289 (2): R596–R604.
doi:
10.1152/ajpregu.00845.2004.
PMID15802554.
S2CID17426759.
^
abLucot JB (February 1994). "Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin". European Journal of Pharmacology. 253 (1–2): 53–60.
doi:
10.1016/0014-2999(94)90756-0.
PMID8013549.
^Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekström JC, Svenningsson P, et al. (December 2008). "The role of 5-HT(1A) receptors in learning and memory". Behavioural Brain Research. 195 (1): 54–77.
doi:
10.1016/j.bbr.2008.02.023.
PMID18394726.
S2CID140205386.
^Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, et al. (February 2003). "Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory". The American Journal of Psychiatry. 160 (2): 334–340.
doi:
10.1176/appi.ajp.160.2.334.
PMID12562581.
^Kennett GA, Dourish CT, Curzon G (February 1987). "Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression". European Journal of Pharmacology. 134 (3): 265–274.
doi:
10.1016/0014-2999(87)90357-8.
PMID2883013.
^Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC (April 2003). "Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain". Pharmacology. 67 (4): 182–194.
doi:
10.1159/000068404.
PMID12595749.
S2CID25882138.
^
abMillan MJ, Perrin-Monneyron S (March 1997). "Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors". European Journal of Pharmacology. 321 (3): R11–R13.
doi:
10.1016/S0014-2999(97)00050-2.
PMID9085055.
^Prow MR, Martin KF, Heal DJ (December 1996). "8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation". European Journal of Pharmacology. 317 (1): 21–28.
doi:
10.1016/S0014-2999(96)00693-0.
PMID8982715.
^
abMeyer LC, Fuller A, Mitchell D (February 2006). "Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290 (2): R405–R413.
doi:
10.1152/ajpregu.00440.2005.
PMID16166206.
S2CID224414.
^
abPopova NK, Amstislavskaya TG (July 2002). "Involvement of the 5-HT(1A) and 5-HT(1B) serotonergic receptor subtypes in sexual arousal in male mice". Psychoneuroendocrinology. 27 (5): 609–618.
doi:
10.1016/S0306-4530(01)00097-X.
PMID11965359.
S2CID25269315.
^Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (May 2007). "A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")". Neuroscience. 146 (2): 509–514.
doi:
10.1016/j.neuroscience.2007.02.032.
PMID17383105.
S2CID15617471.
^Gudelsky GA, Koenig JI, Meltzer HY (December 1986). "Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors". Neuropharmacology. 25 (12): 1307–1313.
doi:
10.1016/0028-3908(86)90101-2.
PMID2951611.
S2CID2547042.
^Ootsuka Y, Blessing WW (February 2006). "Activation of 5-HT1A receptors in rostral medullary raphé inhibits cutaneous vasoconstriction elicited by cold exposure in rabbits". Brain Research. 1073–1074: 252–261.
doi:
10.1016/j.brainres.2005.12.031.
PMID16455061.
S2CID23178233.
^
abcde"BRINTELLIX (vortioxetine) tablets for oral use. Full Prescribing Information, Section 12.2 (Pharmacodynamics)." Takeda Pharmaceuticals America Inc. and Lundbeck, 2013. Revised September 2013.
[1]Archived 2019-09-18 at the
Wayback Machine
^Saxena PR, Lawang A (October 1985). "A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors". Archives Internationales de Pharmacodynamie et de Therapie. 277 (2): 235–252.
PMID2933009.
^Cao BJ, Rodgers RJ (October 1998). "Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice". Psychopharmacology. 139 (3): 185–194.
doi:
10.1007/s002130050703.
PMID9784072.
S2CID9466299.
^Harrison AA, Parsons LH, Koob GF, Markou A (January 1999). "RU 24969, a 5-HT1A/1B agonist, elevates brain stimulation reward thresholds: an effect reversed by GR 127935, a 5-HT1B/1D antagonist". Psychopharmacology. 141 (3): 242–250.
doi:
10.1007/s002130050831.
PMID10027505.
S2CID19974789.
^Chojnacka-Wójcik E, Kłodzińska A, Tatarczyńska E (February 2005). "The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action". The Journal of Pharmacy and Pharmacology. 57 (2): 253–257.
doi:
10.1211/0022357055399.
PMID15720791.
S2CID20743875.
^Lin D, Parsons LH (April 2002). "Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-maze". Pharmacology, Biochemistry, and Behavior. 71 (4): 581–587.
doi:
10.1016/S0091-3057(01)00712-2.
PMID11888549.
S2CID21610537.
^
abTatarczyńska E, Kłodzińska A, Stachowicz K, Chojnacka-Wójcik E (December 2004). "Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression". Behavioural Pharmacology. 15 (8): 523–534.
doi:
10.1097/00008877-200412000-00001.
PMID15577451.
S2CID6940756.
^
abEriksson TM, Madjid N, Elvander-Tottie E, Stiedl O, Svenningsson P, Ogren SO (June 2008). "Blockade of 5-HT 1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission". Neuropharmacology. 54 (7): 1041–1050.
doi:
10.1016/j.neuropharm.2008.02.007.
hdl:
10616/40922.
PMID18394658.
S2CID207223573.
^
abMcCreary AC, Bankson MG, Cunningham KA (September 1999). "Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors". The Journal of Pharmacology and Experimental Therapeutics. 290 (3): 965–973.
PMID10454466.
^Amital D, Fostick L, Sasson Y, Kindler S, Amital H, Zohar J (May 2005). "Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo-controlled study". European Neuropsychopharmacology. 15 (3): 279–282.
doi:
10.1016/j.euroneuro.2004.12.002.
PMID15820416.
S2CID8382188.
^Feuerstein TJ, Hüring H, van Velthoven V, Lücking CH,
Landwehrmeyer GB (May 1996). "5-HT1D-like receptors inhibit the release of endogenously formed [3H]GABA in human, but not in rabbit, neocortex". Neuroscience Letters. 209 (3): 210–214.
doi:
10.1016/0304-3940(96)12637-9.
PMID8736648.
S2CID27376524.
^
abBubar MJ, Cunningham KA (2006). "Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence". Current Topics in Medicinal Chemistry. 6 (18): 1971–1985.
doi:
10.2174/156802606778522131.
PMID17017968.
^Schreiber R, Melon C, De Vry J (February 1998). "The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test". Psychopharmacology. 135 (4): 383–391.
doi:
10.1007/s002130050526.
PMID9539263.
S2CID22677071.
^
abPopova NK, Amstislavskaya TG (July 2002). "5-HT2A and 5-HT2C serotonin receptors differentially modulate mouse sexual arousal and the hypothalamo-pituitary-testicular response to the presence of a female". Neuroendocrinology. 76 (1): 28–34.
doi:
10.1159/000063681.
PMID12097814.
S2CID42319246.
^Duxon MS, Kennett GA, Lightowler S, Blackburn TP, Fone KC (1997). "Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat". Neuropharmacology. 36 (4–5): 601–608.
doi:
10.1016/S0028-3908(97)00042-7.
PMID9225285.
S2CID41471226.
^Kennett GA, Trail B, Bright F (December 1998). "Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated". Neuropharmacology. 37 (12): 1603–1610.
doi:
10.1016/S0028-3908(98)00115-4.
PMID9886683.
S2CID7310462.
^Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, et al. (1997). "SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist". Neuropharmacology. 36 (4–5): 609–620.
doi:
10.1016/S0028-3908(97)00038-5.
PMID9225286.
S2CID23032157.
^
abMillan MJ, Brocco M, Gobert A, Dekeyne A (February 2005). "Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade". Psychopharmacology. 177 (4): 448–458.
doi:
10.1007/s00213-004-1962-z.
PMID15289999.
S2CID20866665.
^
abDekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, et al. (September 2008). "S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models". Psychopharmacology. 199 (4): 549–568.
doi:
10.1007/s00213-008-1177-9.
PMID18523738.
S2CID25063495.
^Fujitsuka N, Asakawa A, Hayashi M, Sameshima M, Amitani H, Kojima S, et al. (May 2009). "Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin". Biological Psychiatry. 65 (9): 748–759.
doi:
10.1016/j.biopsych.2008.10.031.
PMID19058784.
S2CID22053616.
^Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S (April 1997). "5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists". European Journal of Pharmacology. 325 (1): 9–12.
doi:
10.1016/S0014-2999(97)89962-1.
PMID9151932.
^Stancampiano R, Melis MR, Argiolas A (August 1994). "Penile erection and yawning induced by 5-HT1C receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission". European Journal of Pharmacology. 261 (1–2): 149–155.
doi:
10.1016/0014-2999(94)90313-1.
PMID8001637.
^
abPitsikas N, Brambilla A, Borsini F (January 1994). "Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task". Pharmacology, Biochemistry, and Behavior. 47 (1): 95–99.
doi:
10.1016/0091-3057(94)90116-3.
PMID8115433.
S2CID21800364.
^Compan V, Charnay Y, Dusticier N, Daszuta A, Hen R, Bockaert J (2004). "[Feeding disorders in 5-HT4 receptor knockout mice]". Journal de la Société de Biologie. 198 (1): 37–49.
doi:
10.1051/jbio/2004198010037.
PMID15146954.
S2CID90408378.
^
abFontana DJ, Daniels SE, Wong EH, Clark RD, Eglen RM (1997). "The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation". Neuropharmacology. 36 (4–5): 689–696.
doi:
10.1016/S0028-3908(97)00055-5.
PMID9225295.
S2CID46510811.
^Galeotti N, Ghelardini C, Bartolini A (September 1998). "Role of 5-HT4 receptors in the mouse passive avoidance test". The Journal of Pharmacology and Experimental Therapeutics. 286 (3): 1115–1121.
PMID9732367.
^Wesołowska A (February 2008). "The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors". European Journal of Pharmacology. 580 (3): 355–360.
doi:
10.1016/j.ejphar.2007.11.022.
PMID18096153.
^
abWesołowska A, Nikiforuk A (April 2007). "Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression". Neuropharmacology. 52 (5): 1274–1283.
doi:
10.1016/j.neuropharm.2007.01.007.
PMID17320917.
S2CID22664564.
^Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, et al. (December 2006). "SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models". European Journal of Pharmacology. 553 (1–3): 109–119.
doi:
10.1016/j.ejphar.2006.09.049.
PMID17069795.
^
abPerez-García G, Meneses A (July 2005). "Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task". Pharmacology, Biochemistry, and Behavior. 81 (3): 673–682.
doi:
10.1016/j.pbb.2005.05.005.
PMID15964617.
S2CID19789219.
^Wesołowska A, Nikiforuk A (March 2008). "The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats". European Journal of Pharmacology. 582 (1–3): 88–93.
doi:
10.1016/j.ejphar.2007.12.013.
PMID18234190.
^Alcalde E, Mesquida N, López-Pérez S, Frigola J, Mercè R (Feb 2009). "Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists". Journal of Medicinal Chemistry. 52 (3): 675–87.
doi:
10.1021/jm8009469.
PMID19159187.
^
abWesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (September 2006). "Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression". Neuropharmacology. 51 (3): 578–586.
doi:
10.1016/j.neuropharm.2006.04.017.
PMID16828124.
S2CID39928418.
^Gasbarri A, Cifariello A, Pompili A, Meneses A (December 2008). "Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat". Behavioural Brain Research. 195 (1): 164–170.
doi:
10.1016/j.bbr.2007.12.020.
PMID18308404.
S2CID12910296.
^Liy-Salmeron G, Meneses A (2008). "Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model". Hippocampus. 18 (9): 965–974.
doi:
10.1002/hipo.20459.
PMID18570192.
S2CID20937527.
^
abBonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R, et al. (May 2007). "Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents". The Journal of Pharmacology and Experimental Therapeutics. 321 (2): 690–698.
doi:
10.1124/jpet.107.119404.
PMID17314195.
S2CID14579645.
^Saxena PR, De Vries P, Villalón CM (August 1998). "5-HT1-like receptors: a time to bid goodbye". Trends in Pharmacological Sciences. 19 (8): 311–316.
doi:
10.1016/S0165-6147(98)01228-0.
PMID9745358.